Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danilo Perrotti

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Current Drug Targets|June 17, 2016
Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell InterplayDanilo Perrotti, Giovannino Silvestri, Lorenzo Stramucci, et al.
Blood|April 19, 2003
Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiationKaren Keeshan, Giorgia Santilli, Francesca Corradini, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 28, 2006
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomesShih-Jiuan Chiu, Shujun Liu, Danilo Perrotti, et al.
Blood|June 22, 2006
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activitiesYoung-Jin Lee, Letetia C Jones, Nikolai A Timchenko, et al.
Molecular and Cellular Biology|March 9, 2002
hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesisAngela Iervolino, Giorgia Santilli, Rossana Trotta, et al.
Science Translational Medicine|July 19, 2019
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"Danilo Perrotti, Anupriya Agarwal, Claire M Lucas, et al.
Oncotarget|July 5, 2016
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stressKshama A Doshi, Rossana Trotta, Karthika Natarajan, et al.
Nucleic Acids Research|February 1, 2007
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS methodZhongfa Liu, Shujun Liu, Zhiliang Xie, et al.
Blood|March 27, 2014
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cellsAmy M Cook, Liang Li, Yinwei Ho, et al.
Molecular Cancer Research : MCR|April 2, 2015
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasNidal Muvarak, Shannon Kelley, Carine Robert, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Current Drug Targets|June 17, 2016
Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell InterplayDanilo Perrotti, Giovannino Silvestri, Lorenzo Stramucci, et al.
Blood|April 19, 2003
Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiationKaren Keeshan, Giorgia Santilli, Francesca Corradini, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 28, 2006
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomesShih-Jiuan Chiu, Shujun Liu, Danilo Perrotti, et al.
Blood|June 22, 2006
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activitiesYoung-Jin Lee, Letetia C Jones, Nikolai A Timchenko, et al.
Molecular and Cellular Biology|March 9, 2002
hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesisAngela Iervolino, Giorgia Santilli, Rossana Trotta, et al.
Science Translational Medicine|July 19, 2019
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"Danilo Perrotti, Anupriya Agarwal, Claire M Lucas, et al.
Oncotarget|July 5, 2016
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stressKshama A Doshi, Rossana Trotta, Karthika Natarajan, et al.
Nucleic Acids Research|February 1, 2007
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS methodZhongfa Liu, Shujun Liu, Zhiliang Xie, et al.
Blood|March 27, 2014
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cellsAmy M Cook, Liang Li, Yinwei Ho, et al.
Molecular Cancer Research : MCR|April 2, 2015
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasNidal Muvarak, Shannon Kelley, Carine Robert, et al.
Pageof 9